InterCure Ltd.
INCR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.92 | 0.01 | 0.02 | -1.52 |
| FCF Yield | -25.85% | -26.46% | 6.01% | 1.42% |
| EV / EBITDA | -7.97 | -12.85 | 7.80 | 21.95 |
| Quality | ||||
| ROIC | -9.18% | -6.59% | 6.33% | 1.93% |
| Gross Margin | 12.66% | 29.56% | 39.90% | 41.48% |
| Cash Conversion Ratio | 0.92 | 0.84 | 1.17 | 3.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.98% | 17.41% | 81.47% | 190.88% |
| Free Cash Flow Growth | -26.76% | -278.43% | 186.83% | 184.30% |
| Safety | ||||
| Net Debt / EBITDA | -2.59 | -3.96 | 0.32 | -2.80 |
| Interest Coverage | -3.26 | -1.72 | 3.45 | 5.59 |
| Efficiency | ||||
| Inventory Turnover | 1.66 | 2.36 | 1.59 | 1.89 |
| Cash Conversion Cycle | 359.45 | 103.34 | 78.42 | 72.03 |